Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Evaluating the efficacy and safety of treatment with Tislelizumab in combination with S-1 in patients with high-risk recurrent intrahepatic cholangiocarcinoma after radical surgery
Intrahepatic Cholangiocarcinoma
DRUG: Tislelizumab combined with S-1
1-year RFS rate, Proportion of patients with no local, regional, or metastatic ICC or death from any cause (whichever occurs first) 12 months after hepatectomy., 12 months
RFS, Time from hepatectomy to the first documented occurrence of local, regional, or metastatic ICC or death from any cause, whichever occurs first., 24 months|OS, Time from hepatectomy to first recorded occurrence of death from any cause, 24 months|Survival time after recurrence, The time from the first documented occurrence of localized, regional, or metastatic ICC, whichever occurs first, to death from any cause., 24 months|AEs AEs AEs AEs AE, Adverse Events (AEs)The grade of AEs and the number of patients with AEs are assessed based on CTCAE v5.0, 24 months
Evaluating the efficacy and safety of treatment with Tislelizumab in combination with S-1 in patients with high-risk recurrent intrahepatic cholangiocarcinoma after radical surgery